Clinical trials: Acute Respiratory Distress Syndrome (ARDS)
COVID-19, ARDS
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
Coronavirus disease (COVID-19) is a current pandemic infection caused by an RNA virus called Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
- Trial name
- COVIDANCE (NCT04643691)
- Testing
- Losartan 50 mg and Spironolactone 25 mg pillules oral use
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Respiratory Distress Syndrome In Premature Infants, Preterm Infants
Respiratory Pattern During Neurally Adjusted Ventilator Assist (NAVA) in Preterm Infants
This study is to investigate the effect of a wide range of assistance levels on respiratory pattern, breathing variability including tidal volume and peak inspiratory pressure during neurally adjusted ventilatory assist (NAVA) in…
- Trial name
- NCT02770976
- Testing
- Increasing and decreasing NAVA levels with 10-min intervals
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Inha University Hospital
Acute Respiratory Distress Syndrome, Cardiogenic Shock
Closed Loop Mechanical Ventilation and ECMO
Mechanical ventilation and ECMO are both technologies interacting on gas exchange. Nevertheless, besides a consensus paper, no evidence-based guidelines regarding protective lung ventilation on ECMO exist to date.
- Trial name
- NCT04925518
- Testing
- Closed Loop Mechanical Ventilation, Conventional Mechanical Ventilation
- Volunteers
- 62 people
- Sponsor
- University of Zurich
COVID, Acute Respiratory Distress Syndrome
Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)
The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU).
- Trial name
- COVID-ARA2 (NCT04337190)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Cerebral Blood Flow
Prone Positioning for Brain-injured Patients With Severe ARDS (ProBrain)
Prone position (PP) is a key component to treat hypoxemia in patients with severe acute respiratory distress syndrome (ARDS). However, most studies evaluating PP effects in patients with ARDS exclude those with brain-injuries…
- Trial name
- ProBrain (NCT05050838)
- Testing
- Transcranial Doppler (TCD)
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Respiratory Distress Syndrome, Newborn
The Use of Heliox Via Nasal CPAP to Prevent Early CPAP Failure in Premature Infants: A Feasibility Study
The purpose of this study is to evaluate the safety and utility of using heliox gas in combination with nasal CPAP in premature infants.
- Trial name
- NCT00739115
- Testing
- Heliox gas
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Hawaii Pacific Health
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
NCPAP + Heliox as a Treatment for Infant Respiratory Distress Syndrome (RDS)
Infants born between 28 and 32 weeks' gestation with radiological findings and clinical symptoms of moderate RDS, requiring respiratory support with Nasal Continuous Positive Airway Pressure (NCPAP) within the first hour of life…
- Trial name
- NCT01383850
- Testing
- NCPAP + standard air, NCPAP + Heliox
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Sepsis, Pneumonia
Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project
The purpose of this study is to determine whether an integrated EmONC package (community mobilization, training of community-based health care providers and a maternal and neonatal health pack) reduce perinatal and neonatal…
- Conditions
- Sepsis, Pneumonia, Omphalitis, Birth Asphyxia
- Trial name
- EmONC (NCT01751945)
- Testing
- EmONC package
- Where
- Pakistan
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Respiratory Distress Syndrome, Pre-term Infants
Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome
This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham).
- Trial name
- NCT06776783
- Testing
- APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 520 people
- Sponsor
- Aerogen Pharma Limited
Preterm Infants
NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)
The investigators compared advantages and disadvantages of two forms of noninvasive respiratory support -noninvasive high-frequency oscillatory ventilation (nHFOV) or nasal continuous positive airway pressure (nCPAP) -as a…
- Trial name
- NCT03099694
- Testing
- noninvasive high-frequency ventilation (nHFOV), nasal continuous positive airway pressure (nCPAP)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Xingwang Zhu
Acute Respiratory Distress Syndrome, Lung Diseases
Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome
The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS.
- Trial name
- NCT00295269
- Testing
- Mythylprednisolone
- Volunteers
- 200 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
Acute Respiratory Distress Syndrome, Viral or Bacterial Infections
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy.
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral
- Trial name
- NCT05123755
- Testing
- AV-001 Injection
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vasomune Therapeutics, Inc.
PreTerm Neonate, Respiratory Distress Syndrome (RDS)
Neonatologist-Performed Lung Ultrasound (NPLUS) to Guide Respiratory Therapy
The goal of this cross-over clinical trial is to evaluate whether Neonatologist-Performed Lung Ultrasound (NPLUS) can be used in preterm babies on non-invasive breathing support to reduce the amount of oxygen they need.
- Trial name
- NCT06901206
- Testing
- Neonatologist performed lung ultrasound
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Royal Hospital For Women
ARDS (Acute Respiratory Distress Syndrome)
Free for Weaning ECMO vs Respiratory Driven Study
In its most severe form, Acute Respiratory Distress Syndrome (ARDS) may require the use of veno-venous ECMO (vvECMO). While the criteria for vvECMO indication, ECMO settings, and ventilator management are relatively well-defined…
- Trial name
- FORWARD (NCT06876415)
- Testing
- P0.1 and delta Poeso integration into the decanulation decision
- Where
- 4 sites in France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Respiratory Distress Syndrome
Effect of High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure
Respiratory distress syndrome (RDS) in preterm babies is caused by a deficiency of lung surfactant. The risk of RDS increases with decreasing gestational age, and is almost inevitable in babies born at less than 28 weeks…
- Trial name
- NCT05849116
- Volunteers
- 100 people
- Sponsor
- Assiut University
Respiratory Distress Syndrome, Newborn
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
A multicenter, double blind, randomized, single dose, active-controlled study to investigate the efficacy and safety of synthetic surfactant (CHF 5633) in comparison to porcine surfactant (Poractant alfa, Curosurf ®) in the…
- Trial name
- NCT02452476
- Testing
- CHF5633, Poractant alfa
- Where
- 23 sites in United States
- Volunteers
- 123 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Acute Respiratory Distress Syndrome (ARDS), COVID-19
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
The purpose of our prospective monocentric, randomized, controlled trial is to evaluate the effects of intravenous lidocaine on gas exchange and inflammation in acute respiratory distress syndrome (ARDS) due or not to Covid-19…
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), COVID-19, Corona Virus Infection
- Trial name
- LidoCovid (NCT04609865)
- Testing
- Lidocaine 2%, Control
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Strasbourg, France
Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
A research study that will evaluate if giving surfactant medication to premature babies weighing < 1250 gm at birth during the second and third weeks of life will help their lungs.
- Trial name
- NCT00208039
- Testing
- Infasurf
- Volunteers
- 89 people
- Sponsor
- Children's Hospital of Philadelphia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.